In Vitro Diagnostics:
Oncology & Infectious Diseases Conference

Transitioning towards better turnaround time for efficient patient care

9th - 10th November 2016, London, UK

Supporting Association: BIVDA

Event Overview:
Ageing population, rising chronic lifestyle diseases and increasing usage of point of care testing are the driving factors for the growth of in vitro diagnostics industry.

The industry has also witnessed positive support in form of funding by NIHR to NHS Trust to improve the way diseases are diagnosed by forming DEC (Diagnostic Evidence Cooperatives), 6 new pathology projects, for better patient care and improved efficiency. Technological advancements have led to new variety of diagnostic tests, allowing patients to access novel treatments earlier.

In Vitro Diagnostics in Oncology and Infectious Diseases Conference to be held on 9th-10th November 2016 in London, UK, aims to bring people together from hospitals, reference laboratories in academic institutes and IVD industry leaders to discuss the potential growth of IVD in Oncology and Infectious Diseases and the challenges faced. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the attendees an opportunity to understand the current issues faced.

Key Highlights:

ONCOLOGY
- Upcoming regulations impacting on health care providers and IVD companies
- Early diagnosis of cancer using various technologies and methods
- Novel markers for various types of cancer and their challenges
- Study of mutation and the predictability for cancer recurrence
- Quality assurance, high throughput and controls

INFECTIOUS DISEASES
- Upcoming regulations impacting on health care providers and IVD companies
- Molecular testing and diagnostics using PCR and mass spectrometer
- Rapid testing and diagnostics for various infectious diseases
- Quality control of point of care and its advancements
- Effectiveness of anti-microbial resistance and POCT with new AMR stewardship provisions

Who should attend?
From Hospitals, Reference Laboratory and Academics: Directors, head of laboratory, lab managers, deputy lab managers, chief/head biomedical scientist, laboratory technician, professors, associate professors, research fellow, POCT lead

For more information please contact Ajay at ajay.nimbalkar@mnmconferences.com | +91 20 3010 8285
In Vitro Diagnostics:
Oncology & Infectious Diseases Conference
9th - 10th November 2016, London, UK

Sponsors/Exhibitors:

ELITechGroup
FUJIFILM
chemomettec

HORIBA

Supporting Associations:
ESCMI
BIVDA
MEDEC
Holland
BIO
Swiss Biotech Association
BioPartner
obn
UK Sciences & Stratospheric Medicine
Eurobiomed
asebio
bionow
MediWales

Media Partners:

Farmavita
CrowdReviews
MEDGENER
PharmaVOICE
iptechex
TECHNOLOGY NETWORKS
the Pathologist
Labhoo.com
GEN
LABIOTECH.eu
SelectScience
Bio-Equip
In Vitro Diagnostics:
Oncology & Infectious Diseases Conference
9th - 10th November 2016, London, UK

Confirmed Speakers:

Doris-Ann Williams
Chief Executive
British in Vitro Diagnostics Association (BIVDA)

Dr. Jean-Christophe Bourdon
Senior Lecturer, Cellular & Molecular Biology,
University of Dundee, Scotland, UK

Prof. Dr. Viviane van hoof
Clinical Pathologist and Head of the Department of Clinical Chemistry
University of Antwerp, Antwerp

Prof. Richard O’Kennedy
Scientific Director,
Biomedical Diagnostics Institute, Dublin City University, Dublin

Anders Larsson
Professor Department of Medical Sciences, Biochemical Structure and Function
Uppsala University, Sweden

Dr. Catharine Sturgeon
Consultant Clinical Scientist, Department of Clinical Biochemistry & Director, The National External Quality Assessment Service proficiency-testing center/Royal Infirmary of Edinburgh

Dr. Manfred Dietel
Director of the Institute of Pathology
University Hospital Charité

Dr. Kate Templeton
Consultant Clinical Scientist
Royal Infirmary of Edinburgh

Prof. John Simpson
Dean of Research and Innovation (Clinical) & Director of the NIHR Diagnostic Evidence Cooperative
Newcastle University, UK

Dr. Panagiotis Pantelidis
Divisional Consultant Scientist, Pathology
Imperial College Healthcare
NHS Trust, UK

Dr. Philip Wood
Clinical Director
Leeds Teaching Hospitals NHS Trust, UK

Dr. Peter Coyle
Consultant Virologist and Clinical Director
Virus Reference Laboratory, The Royal Victoria Hospital, Ireland

Prof. Dr. Thomas Lion
Medical Director
St. Anna Kinderkrebshoschung, Austria

Dr. Mohammad Raza
Consultant Virologist and Honorary Senior Clinical Lecturer
University of Sheffield, UK

Dr. Helen Reeves
Senior Lecturer & Honorary Consultant Gastroenterologist
Newcastle Hospitals NHS Foundation Trust, Newcastle University, UK

Dr. Gerrit Meijer
Head of the Department, Department of Pathology
The Netherlands Cancer Institute

Dr. Manuel Salto-Tellez
Chair of Molecular Pathology,
Queen’s University Belfast Clinical Consultant Pathologist,
The Belfast Health and Social Care Trust | Deputy Director, Centre for Cancer Research and Cell Biology

Dr. John Timms
Reader in Cancer Prometics
University College London, UK

Prof. A.P.R. Wilson
Consultant Microbiologist
UCLH NHS Foundation Trust, UK

Michael Duffy
Professor, Department of Pathology and Laboratory Medicine
St Vincent’s University Hospital, Dublin

Dr. Ian A. Cree
Molecular Pathologist, University Hospitals Coventry and Warwickshire, UK

Prof. Richard O’Kennedy
Scientific Director,
Biomedical Diagnostics Institute, Dublin City University, Dublin

Prof. A.P.R. Wilson
Consultant Microbiologist
UCLH NHS Foundation Trust, UK

Ming-Qing Du,
Professor of Oncological Pathology, Honorary Consultant Molecular Pathologist Division of Molecular Histopathology, Department of Pathology University of Cambridge

Dr. Olivier Denis
Microbiologist, Department of Microbiology Hospital Erasme

Dr. Andreas Erich Zautner
Professor of Microbiology
Universitätsmedizin Göttingen

Dr. Anthony Bench
Principal Clinical Scientist, Molecular Malignancy Laboratory & Haematology-Oncology Diagnostic Service, Pathology, Cambridge University Hospitals NHS Foundation Trust

Prof. Dr. Tom Lion
Medical Director
St. Anna Kinderkrebshoschung, Austria

Prof. Dr. Viviane van hoof
Clinical Pathologist and Head of the Department of Clinical Chemistry
University of Antwerp, Antwerp

Prof. Dr. Viviane van hoof
Clinical Pathologist and Head of the Department of Clinical Chemistry
University of Antwerp, Antwerp

Dr. Panagiottis Pantelitis
Divisional Consultant Scientist, Pathology
Imperial College Healthcare
NHS Trust, UK

Dr. Philip Wood
Clinical Director
Leeds Teaching Hospitals NHS Trust, UK

Dr. Peter Coyle
Consultant Virologist and Clinical Director
Virus Reference Laboratory, The Royal Victoria Hospital, Ireland

Prof. Dr. Thomas Lion
Medical Director
St. Anna Kinderkrebshoschung, Austria

Dr. Mohammad Raza
Consultant Virologist and Honorary Senior Clinical Lecturer
University of Sheffield, UK

Dr. Helen Reeves
Senior Lecturer & Honorary Consultant Gastroenterologist
Newcastle Hospitals NHS Foundation Trust, Newcastle University, UK

Dr. Gerrit Meijer
Head of the Department, Department of Pathology
The Netherlands Cancer Institute

Dr. Manuel Salto-Tellez
Chair of Molecular Pathology,
Queen’s University Belfast Clinical Consultant Pathologist,
The Belfast Health and Social Care Trust | Deputy Director, Centre for Cancer Research and Cell Biology

Dr. John Timms
Reader in Cancer Prometics
University College London, UK

For more information please contact Ajay at ajay.nimbalkar@mnmconferences.com | +91 20 3010 8285
In Vitro Diagnostics: Oncology & Infectious Diseases Conference
9th - 10th November 2016, London, UK

Day 1, Wednesday 9th November 2016

08:15 Registration
08:55 Welcome note from MnM Conferences
09:00 Opening Remarks from the Chairman
09:10 Regulations for In-house Development of New Markers
  • Impact on health care providers
  • Impact on diagnostics companies

09:40 Impact of the IVD Regulations
  • Key changes
  • Timeline
  • New classifications
  • Clinical evidence
  Doris-Ann Williams, Chief Executive, British in Vitro Diagnostics Association (BIVDA)

10:10 Pricing and Reimbursement Challenges for In Vitro Diagnostics

10:40 Solution Provider Presentation: Please contact Steve Hambrook at steve.h@mnmconferences.com

10:55 Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

Stream A

<table>
<thead>
<tr>
<th>Oncology</th>
<th>Infectious Diseases</th>
</tr>
</thead>
</table>
| Moving from research to routine - Quality control essential   | Molecular Diagnostics and its Technologies
  • Early investigation of pre-analytical factors that may influence interpretation of results.
  • Internal quality control procedures should be introduced as early as possible to assess reproducibility.
  • Internal quality control procedures may be further developed and sample exchange between laboratories may be appropriate.
  • Once use of a new biomarker has been accepted into clinical practice, early and on-going provision of external quality assessment (proficiency testing) is essential to ensure that results obtained in different laboratories are comparable.
  Dr. Catharine Sturgeon, Consultant Clinical Scientist, Department of Clinical Biochemistry & Director of Laboratories, The National External Quality Assessment Service Proficiency-Testing Center/Royal Infirmary of Edinburgh |
| 11:40 Moving from research to routine - Quality control essential   | 11:40 Linking molecular diagnostics to clinical outcome
  • Clinical Challenges
  • Clinical Opportunities
  • Need for better clinical integration
  • Need for better patient focused services
  Dr Peter Coyle, Consultant Virologist and Clinical Director, Virus Reference Laboratory, the Royal Victoria Hospital, Ireland |
| 12:10 Solution Provider Presentation: Please contact Steve Hambrook at steve.h@mnmconferences.com | 12:10 Solution Provider Presentation: Please contact Steve Hambrook at steve.h@mnmconferences.com |
| 12:40 Role of high throughput in molecular testing          | 12:40 The future of multiplex PCR assays in diagnosing MDR pathogen
  Dr Kate Templeton, Consultant Clinical Scientist, Royal Infirmary of Edinburgh |
| 13:10 Lunch and Poster Presentation | One-to-One Networking Meetings |
| 14:10 Quality assurances in Path lab                         | 14:10 Shift from culture screening to molecular testing
  Dr Panagiotis Pantelidis, Divisional Consultant Scientist, Pathology, Imperial College Healthcare NHS Trust, UK |
| Early Diagnosis and Treatment of Cancer                      | Early Detection and Rapid Diagnostics for Various Infectious Diseases
  Dr. Manuel Salto-Tellez, Chair of Molecular Pathology, Queen’s University Belfast | 14:40 Biomarkers for early detection of ventilator associated pneumonia
  \ Prof. John Simpson, Dean of Research and Innovation (Clinical) & Director of the NIHR Diagnostic Evidence Cooperative, Newcastle University, UK |
| 14:40 Applications of NGS technology for cancer diagnostics in universal healthcare systems – scientific and financial considerations
  • NGS validation models and cost-effectiveness
  • NGS choice of panels
  • NGS clinical interpretation
  • NGS and healthcare systems
  Dr. Manuel Salto-Tellez, Chair of Molecular Pathology, Queen’s University Belfast |

Stream B
### Oncology

**15:10 Early diagnosis in cancer**
- Early diagnosis of cancer is critical to improving outcomes and patient experience, and is central to the National Cancer Taskforce strategy.
- Leeds Teaching Hospitals continues to develop pathways for earlier cancer diagnosis, and the Leeds Cancer Centre is collaborating with partners across the health economy in projects to identify cancer earlier, and to provide diagnostic information more rapidly.
- The challenge for diagnostics is to:
  - provide more rapid, less invasive methods for cancer detection
  - embrace the genomic era to facilitate individualised care
  - provide effective ways of monitoring targeted therapy and patient response

  **Dr Philip Wood**, Clinical Director, Leeds Teaching Hospitals NHS Trust, UK

### Infectious Diseases

**15:10 Rapid diagnostics in the acute care setting – tests for influenza**
- **Dr. Mohammad Raza**
  - Consultant Virologist and Honorary Senior Clinical Lecturer

### Stream A

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:10</td>
<td>Early diagnosis in cancer</td>
<td>Dr Philip Wood, Clinical Director, Leeds Teaching Hospitals NHS Trust, UK</td>
</tr>
<tr>
<td>16:25</td>
<td>The role of liquid biopsy in cancer detection, diagnosis and monitoring</td>
<td>Dr. Ian A. Cree, Molecular Pathologist, University Hospitals Coventry and Warwickshire, UK</td>
</tr>
<tr>
<td>16:55</td>
<td>Comparison on circulating tumor cells and cell-free DNA for liquid biopsy</td>
<td></td>
</tr>
<tr>
<td>17:25</td>
<td>Early detection of cancer using proteomic technologies</td>
<td>Dr. John Timms, Reader in Cancer Prometics, University College London, UK</td>
</tr>
<tr>
<td>17:55</td>
<td>Closing remarks from the Chairman</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Drinks Reception &amp; Networking</td>
<td></td>
</tr>
</tbody>
</table>

### Stream B

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
</table>
| 15:10 | Rapid diagnostics in the acute care setting – tests for influenza    | Dr. Mohammad Raza
  - Consultant Virologist and Honorary Senior Clinical Lecturer |
| 15:40 | Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings |
| 16:25 | Diagnostic monitoring of adenovirus infections in the immunocompromised host | Prof Dr Thomas Lion, Medical director
  - St. Anna Kinderkrebshorschung |
| 16:55 | Rapid and effective screening for MRSA, VRE, and CPO due to the diversity of strains | Olivier Denis, Microbiologist, Department of Microbiology
  - Hospital Erasme |
| 17:25 | Rapid diagnostics for early detection of tuberculosis                |                                                                   |
| 17:55 | Closing remarks from the Chairman                                    |                                                                   |

For more information please contact Ajay at ajay.nimbalkar@mnmconferences.com | +91 20 3010 8285
### Day 2, Thursday 10th November 2016

#### Oncology

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:55</td>
<td>Welcome note from MnM Conferences</td>
</tr>
<tr>
<td>09:00</td>
<td>Opening Remarks from the Chairman</td>
</tr>
</tbody>
</table>
| 09:10 | The predictive potential of circulating tumour cells  
- Focused on patients with primary liver cancer  
- Summarising drawbacks and advantages of CTC versus biopsy tissue  
- Overview of methods to characterise CTC  
- Imagestream Enumeration and prognosis in HCC  
- Exploring CTC biomarkers for stratification of therapy  
  
**Dr. Helen Reeves**  
Senior Lecturer & Honorary Consultant Gastroenterologist  
Newcastle Hospitals NHS Foundation Trust, Newcastle University, UK |
| 09:40 | NGS sequencing using FFPE tissues  
**Ming-Qing Du**  
Professor of Oncological Pathology, Honorary Consultant Molecular Pathologist | Division of Molecular Histopathology, Department of Pathology  
University of Cambridge |

#### Infectious Diseases

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:55</td>
<td>Welcome note from MnM Conferences</td>
</tr>
<tr>
<td>09:00</td>
<td>Opening Remarks from the Chairman</td>
</tr>
</tbody>
</table>
| 09:10 | Optimising point-of-care platform performance by incorporation of highly defined bio-recognition elements  
- The appropriate selection and use of bio recognition elements e.g. antibodies is crucial to maximise platform performance  
- Recombinant techniques now allow engineering to optimise affinity and specificity  
- It is crucial to address issues associated with immobilisation and orientation to ensure excellent performance levels  
- Automated microfluidics-based approaches offer significant potential when combined with recombinant antibodies  
  
**Prof. Richard O’Kennedy,** Scientific Director, Biomedical Diagnostics Institute, Dublin City University, Dublin |
| 09:40 | Point of care testing for infectious diseases – A Scandinavian perspective  
- Use of POCT CRP in primary care  
- POCT testing for white blood cells  
- Calprotectin as a marker for neutrophil activation  
  
**Anders Larsson,** Professor Department of Medical Sciences, Biochemical Structure and Function, Uppsala University, Sweden |

#### Early Diagnosis and Treatment of Cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:10 | Understanding the criticality of tissue-based mutations diagnostics in human tumors  
- Targeted therapy  
- Druggable mutations  
- Check-point inhibitors  
- Comprehensive cancer center  
  
**Dr. Manfred Dietel**  
Director of the Institute of Pathology  
University Hospital Charité |

#### Point of Care

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:10 | Public health impact of Point-of-care testing  
- Reconsideration of where testing is most effective  
- Qualitative, cost-effective and safe diagnostic care by means of POCT  
- Value-based reimbursement  
- Regulations and guidelines specific for POCT (FDA, CLIA, ISO 22870 …)  
- Internal and external quality control of POCT  
  
**Dr Viviane van hoof**  
Clinical Pathologist and Head of the Department of Clinical Chemistry  
University of Antwerp |

#### Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25</td>
<td>Solution Provider Presentation; Please contact Steve Hambrook at <a href="mailto:steve.h@mnmconferences.com">steve.h@mnmconferences.com</a></td>
</tr>
</tbody>
</table>
| 11:40 | Panel Discussion: Mutations to predict cancer recurrence  
- Role of circulating tumor DNA  
- Role of molecular diagnostics  
- Novel methods for therapy |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25</td>
<td>Solution Provider Presentation: Please contact Steve Hambrook at <a href="mailto:steve.h@mnmconferences.com">steve.h@mnmconferences.com</a></td>
</tr>
</tbody>
</table>
| 11:40 | Panel Discussion: Technology advancements in Point-of-Care Diagnostics for Resource-Limited Settings  
- Easy market access  
- Policy development  
- Scale up implementation |
### Stream A: Oncology

#### Upcoming Challenges in New Markers & Technologies

12:10 The role of molecular genetics for the diagnosis of haematological malignancies  
**Dr. Anthony Bench**, Principal Clinical Scientist  
Molecular Malignancy Laboratory & Haemato-Oncology  
Diagnostic Service, Pathology  
Cambridge University Hospitals NHS Foundation Trust

12:40 Solution Provider Presentation: Please contact Steve Hambrook at steve.h@mnmconferences.com

12:55 Bridging the biomarker innovation gap in cancer diagnostics and treatment  
- Rationale why biomarkers should work as in vitro diagnostics in oncology  
- Reasons why most candidate biomarkers never make it to the clinic  
- Strategies for the way out of this dilemma  
**Dr. Gerrit Meijer**, Head of the Department, Department of Pathology, The Netherlands Cancer Institute

14:25 p53 isoforms as predictive biomarkers of cancer treatment in breast cancer using tumour biopsy  
- To determine whether p53 is expressed as a single protein or as a system of proteins (p53 isoforms) in normal and in cancer tissues  
- To define whether all p53-mediated cell responses can be triggered by p53 isoforms in absence of canonical p53 protein,  
- To investigate how is regulated p53 isoform expression (epigenetic, splicing, protein degradation),  
- To determine how is regulated p53 isoforms oligomerisation and activities in response to damage  
**Dr. Jean-Christophe Bourdon**, Senior Lecturer, Cellular and Molecular Biology, University of Dundee, Scotland

14:55 Personalized treatment for cancer: how biomarkers are showing the way  
- Differentiating between indolent and life-threatening disease, thereby identifying who should or should not receive adjuvant systemic therapy following surgical removal of a primary tumor  
- Identifying upfront those patients who are likely to be responsive or be resistant to a specific therapy  
- Identifying upfront patients who are like to experience severe treatment-related toxicity  
- Monitoring patients who are receiving therapy  
**Prof. Michael Duffy**, Dept. of Pathology and Laboratory Medicine, St Vincent’s University Hospital, Dublin

15:25 Closing remarks from the Chairman

15:30 Afternoon Refreshments

### Stream B: Infectious Diseases

#### Anti-Microbial and Anti-Biotic Resistance

12:10 CRP Point-of-care testing in reducing unnecessary antibiotic prescribing  
- Problems of antimicrobial resistance  
- Management of respiratory tract infections in primary care  
- Evidence-base for CRP POCT in reducing prescribing of antibiotics  
**Professor Jonathan Cooke**  
Visiting Professor in the Infectious Diseases and Immunity Section, Division of Infectious Diseases, Department of Medicine, Imperial College London

12:40 Solution Provider Presentation: Please contact Steve Hambrook at steve.h@mnmconferences.com

13:55 Overview of antimicrobial resistance stewardship provisions in hospitals

14:25 Correlation between Anti-microbial resistance and POCT  
- Emergence of multiresistant pathogens in Europe  
- National incentives for narrowing spectrum of antibiotic prescribing  
- Need for Point of Care testing of antimicrobial susceptibility  
- Longitude Prize  
**Prof A.P.R. Wilson**  
Consultant Microbiologist  
UCLH NHS Foundation Trust

14:55 The rapid detection of systemic sepsis and antibiotic resistance together with improved point-of-care testing for screening  
- Point of care microbiology  
- Mass spectrometry testing  
- Mass spectrometry-based phyloproteomics  
- Next generation sequencing  
**Dr. med. Andreas Erich Zautner**  
Professor of Microbiology  
Universitätsmedizin Göttingen

15:25 Closing remarks from the Chairman

15:30 End of Conference